Paper Details

  1. Home
  2. Paper Details

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

Author: BandekarRajesh, BeksacMeral, CavoMichele, ChariAjai, ClemensPamela L, CohenYael C, EstellJane A, GoldschmidtHartmut, HeuckChristoph, HofmeisterCraig C, JennerMatthew W, KuppensSteven, LandgrenC Ola, MoreauPhilippe, NeffTobias, QiMing, SandhuIrwindeep, SpencerAndrew, VoorheesPeter, WilliamsCatherine, van de DonkNiels W C J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the use of daratumumab in patients with smoldering multiple myeloma (SMM), assessing its efficacy and safety for delaying progression to multiple myeloma (MM).
Paper Details　
Original Abstract of the Article :
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-ris...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326703/

データ提供：米国国立医学図書館（NLM）

Daratumumab for Smoldering Multiple Myeloma: A New Dawn for Early Intervention?

Multiple myeloma, a type of blood cancer, is a challenging disease with various stages of progression. This study explores the potential of daratumumab, a monoclonal antibody, as an early intervention strategy for smoldering multiple myeloma (SMM), a stage characterized by a slow growth rate.

The study’s design, like a carefully crafted compass guiding us through the complexities of cancer treatment, involved a randomized, open-label, multicenter phase 2 trial. Researchers meticulously assessed the effectiveness of daratumumab in patients with intermediate-risk or high-risk SMM, examining its impact on disease progression and response rates.

The results, like a beacon of hope in the desert of cancer research, demonstrate the potential of daratumumab as an early intervention strategy, showing promising results in delaying disease progression and achieving significant response rates.

Daratumumab: A New Chapter in Smoldering Multiple Myeloma Treatment

This study provides compelling evidence supporting the use of daratumumab as an early intervention strategy for smoldering multiple myeloma.

The significant delay in disease progression and high response rates, like a refreshing oasis in the desert of cancer treatment, offer hope for a more effective and timely approach to managing this challenging condition.

Navigating the Desert of Cancer: A New Path to Prevention

This research encourages us to consider the potential of early intervention strategies, like a compass guiding us through the complexities of cancer treatment, for managing diseases like smoldering multiple myeloma.

The promising results of this study highlight the importance of ongoing research in this field, seeking to develop new and effective therapies that can improve patient outcomes and prevent disease progression.

Dr.Camel's Conclusion

This study offers a compelling case for the use of daratumumab as an early intervention strategy for smoldering multiple myeloma, providing hope for a more effective and timely approach to managing this challenging condition.

Date :
  1. Date Completed 2020-10-27
  2. Date Revised 2021-01-13
Further Info :

Pubmed ID

32024950

DOI: Digital Object Identifier

PMC7326703

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.